Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cancer therapeutics - PHusis Therapeutics

Drug Profile

Research programme: cancer therapeutics - PHusis Therapeutics

Alternative Names: PHT-427; PHT-7.3

Latest Information Update: 06 Jun 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PHusis Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action 3-phosphoinositide dependent-protein-kinase-inhibitors; KRAS protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Malignant melanoma; Solid tumours

Most Recent Events

  • 02 Jun 2017 PHT 427 is still in pre-clinical trials for Solid tumours in USA (PHusis Therapeutics website, June 2017)
  • 02 Jun 2017 PHusis plans phase I trials for PHT 427 and PHT 7.3 (PHusis Therapeutics website, June 2017)
  • 01 Apr 2017 Pharmacodynamics data from preclinical trials in Solid tumours presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top